Gene Therapy Reaches XLRS Milestone - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Gene Therapy Reaches XLRS Milestone

Atsena Therapeutics reports positive interim data for XLRS gene therapy

  • May 25, 2026

  • 3 min

Share

Clinical Scorecard: Gene Therapy Reaches XLRS Milestone

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPrimarily affects males, diagnosed in childhood.
Care Setting

Key Highlights

  • Structural and functional improvements observed in treated adults.
  • Foveal schisis closure confirmed in treated adults.
  • Enrollment underway for Part C of the trial.

Guideline-Based Recommendations

Diagnosis

    Management

    • ATSN-201 is being evaluated as a gene therapy treatment option.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Safety findings in pediatric patients consistent with adults.

        Clinical Best Practices

        • Monitor for foveal schisis closure in treated patients.
        • Utilize microperimetry and OCT for assessing treatment outcomes.

        Related Resources & Content

        Original Source(s)

        Gene Therapy Reaches XLRS Milestone

        • May 25, 2026

        Related Content

        Diabetes Risk Scores: Beyond Glucose

        Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

        Nasolacrimal balloon dacryoplasty versus nasolacrimal bi-canalicular intubation for the management of congenital nasolacrimal duct obstruction with a previous failed probing or intubation: a retrospective study

        Large language models provide unsafe answers to patient-posed medical questions